APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Overview

About this study

The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria for Living Donors: 

  • Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African).

Exclusion Criteria for Living Donors: 

  • Participants who are unable or unwilling to provide informed consent.

Inclusion Criteria for Recipients: 

  • Recipients of a kidney transplant from an eligible living or deceased donor with recent African ancestry. 
  • Recipients of multi-organ transplants including a kidney plus an additional organ (i.e., liver, heart, lung, pancreas, etc.) or pediatric en bloc and dual kidney transplants.

Exclusion Criteria for Recipients:

  • Participants who are unable or unwilling to provide informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Harini Chakkera, M.D.

Contact us for the latest status

Contact information:

Nalani Thomas B.S.

(480)342-0349

Thomas.Nalani@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20482098

Mayo Clinic Footer